

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

元光科技

MetaLight Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2605)

**(I) RESIGNATION OF EXECUTIVE DIRECTOR AND
INDEPENDENT NON-EXECUTIVE DIRECTOR;
(II) APPOINTMENT OF EXECUTIVE DIRECTOR AND
INDEPENDENT NON-EXECUTIVE DIRECTOR;
(III) CHANGE OF AUTHORIZED REPRESENTATIVE;
AND
(IV) CHANGES IN COMPOSITION OF BOARD COMMITTEES**

This announcement is made by MetaLight Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

RESIGNATION OF EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that Ms. Lu Lu (呂露) (“**Ms. Lu**”) has tendered her resignation as an executive director to the Company due to a change in work arrangements, with effect from December 31, 2025.

The Board also announces that Dr. Xie Tao (謝濤) (“**Dr. Xie**”) has tendered his resignation as an independent non-executive director to the Company in order to devote more time to his personal affairs. His resignation will take effect on December 31, 2025, and his membership at the audit committee and remuneration committee will also terminate on the same date.

Each of Ms. Lu and Dr. Xie has confirmed to the Company that she/he has no disagreement with the Board and there are no matters relating to their resignations that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude and appreciation to Ms. Lu and Dr. Xie for their valuable contributions to the Company during their terms of office.

APPOINTMENT OF EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Xiao Pingyuan (肖平原) (“**Mr. Xiao**”) and Dr. Xiong Yingfei (熊英飛) (“**Dr. Xiong**”) have been appointed as an executive director and an independent non-executive director, respectively, with effect from December 31, 2025.

The biographical details of Mr. Xiao are set out as follows:

Mr. Xiao Pingyuan, aged 38, joined the Group in 2012 and is currently the Product Director and Co-founder of the Group. He is responsible for the core research and development of the Group’s products. Mr. Xiao has 15 years of experience in software research and development. Prior to joining the Group, Mr. Xiao served as a software engineer at Guanggu Chuangye Street in Wuhan (武漢光穀創業街). Mr. Xiao obtained a Bachelor’s Degree in Bioinformatics from Huazhong University of Science and Technology in 2010.

Mr. Xiao has entered into a letter of appointment with the Company for an initial term of one year commencing from the date of his appointment, which is subject to the provisions of the Memorandum and Articles of Association of the Company (as amended from time to time) and the Corporate Governance Code set out in Appendix C1 of the Listing Rules. He shall retire at the first annual general meeting at which he is eligible for retirement by rotation and, if nominated, be proposed for re-election. Pursuant to the letter of appointment, Mr. Xiao shall not receive any director’s fees for serving as an executive director, except for the remuneration received in respect of his management position with the Company. As of the date of this announcement, Mr. Xiao is interested or deemed to be interested in 32,629,326 shares of the Company (the “**Shares**”), representing approximately 21.15% of the issued share capital of the Company under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed in this announcement, as of the date of this announcement, to the best knowledge and belief of the Board and having made all reasonable enquiries, Mr. Xiao (i) has not held any directorship in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not have, and is not deemed to have, any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations which are required to be disclosed under Part XV of the SFO; (iii) does not hold any other positions in the Group; and (iv) does not have any relationship with any other directors, senior management, substantial shareholders or controlling shareholders (as each respectively defined in the Listing Rules) of the Company.

Save as disclosed in this announcement, there are no other matters relating to the appointment of Mr. Xiao that need to be brought to the attention of the shareholders of the Company and there is no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The biographical details of Dr. Xiong are set out as follows:

Dr. Xiong Yingfei, aged 43, obtained his Ph.D. from the University of Tokyo in Japan in 2009 and worked at the University of Waterloo in Canada from 2009 to 2011. Dr. Xiong has joined Peking University since 2012 and is currently serving as a tenured associate professor under the new tenure system and a deputy director of the Institute of Software. Dr. Xiong's research areas span programming languages and software engineering, with particular focus on areas such as program synthesis, program repair, program analysis and program verification. Dr. Xiong has served as a vice chairman of OOPSLA, an area chairman of ASE, an editor for IEEE TSE and other academic positions, while consistently holding program committee membership at international conferences such as PLDI, ICSE, FSE, OOPSLA, ASE and ISSTA. In addition, Dr. Xiong has received the Outstanding Reviewer Award at ICSE and FSE conferences on five occasions. He has led and undertaken multiple research projects, including the Excellent Young Scientist Fund, the Youth 973 Program and projects under the national key research and development program. Dr. Xiong was awarded the First Prize of the National Technological Invention Award (ranking the 6th), the First Prize of Chinese Institute of Electronics Natural Sciences Award (ranking the 1st), the CCF-IEEE CS Young Computer Scientist Award, and the Ten-Year Most Influential Paper Award from MODELS, and has received the Distinguished Paper Award from ACM SIGSOFT/IEEE TCSE on five occasions. He is currently an ACM distinguished member and the sole representative from China in IFIP WG 2.4.

Dr. Xiong has entered into a letter of appointment with the Company for an initial term of one year commencing from the date of his appointment, which is subject to the provisions of the Memorandum and Articles of Association of the Company (as amended from time to time) and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. He shall retire at the first annual general meeting at which he is eligible for retirement by rotation and, if nominated, be proposed for re-election. Pursuant to the letter of appointment, Dr. Xiong is entitled to receive an annual remuneration of RMB100,000, which was determined by the Board upon the recommendation of the remuneration committee after taking into consideration of the various factors, including remuneration paid by comparable companies, time commitment, duties and responsibilities of Dr. Xiong, the performance and profitability of the Company and prevailing market benchmarks. His remuneration will be reviewed from time to time by the remuneration committee under the authority delegated by the Board.

Save as disclosed in this announcement, as of the date of this announcement, to the best knowledge and belief of the Board and having made all reasonable enquiries, Dr. Xiong (i) has not held any directorship in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not have, and is not deemed to have, any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations which are required to be disclosed under Part XV of the SFO; (iii) does not hold any positions in the Group; and (iv) does not have any relationship with any other directors, senior management, substantial shareholders or controlling shareholders (as each respectively defined in the Listing Rules) of the Company.

Dr. Xiong has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules, (ii) that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules, and (iii) that there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed in this announcement, there are no other matters relating to the appointment of Dr. Xiong that need to be brought to the attention of the shareholders of the Company and there is no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

CHANGE OF AUTHORIZED REPRESENTATIVE

The Board further announces that Dr. Sun Xi (孫熙) has been appointed as an authorized representative under Rule 3.05 of the Listing Rules to succeed Ms. Lu's role of authorized representative, with effect from December 31, 2025.

CHANGES IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that following the resignation of Dr. Xie, Dr. Xiong has been appointed as a member of the audit committee and the remuneration committee, with effect from December 31, 2025.

The Board would like to extend its warmest welcome to Mr. Xiao and Dr. Xiong for their new appointments.

By order of the Board
MetaLight Inc.
Dr. Sun Xi
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, December 23, 2025

As at the date of this announcement, the directors are: (i) Dr. Sun Xi (孫熙), Ms. Qian Jinlei (錢金蕾), Mr. Xu Cheng (許誠) and Ms. Lu Lu (呂露) as executive directors and (ii) Dr. Xie Tao (謝濤), Ms. Su Yu (蘇瑜) and Mr. Huang Xiaoling (黃曉凌) as independent non-executive directors.